2 results about "Chlamydia trachomatis" patented technology

The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

The application discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the technical field of liquid biopsy and microbiome. The cervical cancer plasma circulating microbial marker combination comprises Prevotella, Sneathia, Chlamydia trachomatis, Peptostreptococcus, Fusobacterium, Campylobacter and Haemophilus. The cervical cancer plasma circulating microbial marker combination is used for verifying cervical cancer patients and healthy people, and the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, which indicates that the cervical cancer plasma circulating microbial marker combination can effectively distinguish cervical cancer patients from healthy people, is suitable for early screening of cervical cancer, and has significant clinical screening application value.